300587 Zhejiang Tiantie Industry (A)

DGAP-News: EBD Group: BIO-Europe(R) 2018 to bring 4,000 life science leaders to Copenhagen November 5-7

DGAP-News: EBD Group / Key word(s): Conference
EBD Group: BIO-Europe(R) 2018 to bring 4,000 life science leaders to Copenhagen November 5-7

11.10.2018 / 16:20
The issuer is solely responsible for the content of this announcement.


BIO-Europe(R) 2018 to bring 4,000 life science leaders to Copenhagen November 5-7


Carlsbad, CA and Copenhagen, Denmark - October 11, 2018: How does big pharma expand pipeline opportunities? What are the latest developments in partnering trends with Chinese investors? What innovations are most promising in rare disease and orphan drug development? These and many more industry-relevant questions will be addressed at the 24th annual , a global life science partnering event starting on November 5.

This year's conference takes place in Copenhagen for the first time, in the heart of the Medicon Valley Nordic life science cluster in Copenhagen and southern Sweden, one of the top biopharma hubs in Europe. Registration and event information are available .

Leaders in the life sciences will meet at BIO-Europe to develop partnerships that propel global drug development. High-level executives from pharma, biotech, the investment sector and patient groups are confirmed to attend, and will lead program panels and discussions relevant to the industry.

Featured speakers:

  • Mette Kirstine Agger - Managing Partner, Lundbeckfonden Ventures
  • Khatereh Ahmadi - Executive Director, Business Development and Licensing, MSD
  • Deborah Dunsire - President and CEO, Lundbeck
  • Reza Halse - President, MRL Venture Fund, MSD
  • Jutta Heix - International Advisor, Oslo Cancer Cluster
  • Sir Harpal Kumar - Head, Johnson & Johnson Innovation, EMEA
  • Werner Lanthaler - CEO, Evotec AG
  • Matt Roden - Head, Strategic Corporate Development and Global BD Assessment, Bristol-Myers Squibb
  • Marcus Schindler - Senior VP, Global Drug Discovery, Novo Nordisk R&D
  • Onno van de Stolpe - CEO, Galapagos
  • Guillaume Vignon - Senior VP Business Development, BeiGene Switzerland GmbH

Hot topics

  • How pharma and VC collaborations are changing the industry
  • Business development strategies in I-O: Compete - Combine - Collaborate
  • Microbiome and the implication on other therapeutic areas
  • Europe: The global innovation trailblazer
  • Pediatrics: Searching new drug solutions for the people we love most
  • Partnering opportunities with Chinese investors
  • The current climate of CNS R&D: Lessons learned and new research
  • Commercialization of cell and gene therapies
  • Partnering landscape in advanced therapies
  • Biotech company creation in the EU: The role of EU-based VCs



Startup Slam Copenhagen
Startup Slam is a pitching competition sponsored by Johnson & Johnson Innovation, in partnership with Labiotech, offering emerging entrepreneurs a chance to pitch their innovative technologies to a panel of leading investors, pharma dealmakers, and biotech key opinion leaders.

Digital Medicine Track
Sessions in this emerging field include new "smart" treatments which have the potential to alter the digital medicine landscape, and AI's implications for the future of drug discovery.

Watch video coverage from previous events, interviews with executives and thought leaders in the life science industry and premier content related to the biopharma industry on EBD Group's .

# # #

Additional links and information:

Follow BIO-Europe on Twitter: (hashtag: #BIOEurope).

About EBD Group

EBD Group's overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE(R), that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe(R), BIO-Europe Spring(R), BioPharm America(TM), Biotech Showcase(TM), BioEquity Europe, ChinaBio(R) Partnering Forum, Cell & Gene Connect, China Showcase, and Digital Medicine & Medtech Showcase) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Tune into EBD Group's for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. For more information please visit.

Media contact:

Kari Bennett, EBD Group: ;

European media support

Anne Hennecke, MC Services AG: 22;



11.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


732751  11.10.2018 

fncls.ssp?fn=show_t_gif&application_id=732751&application_name=news&site_id=research_pool
EN
11/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zhejiang Tiantie Industry (A)

Zhejiang Tiantie Industry Co Ltd: 3 directors

A director at Zhejiang Tiantie Industry Co Ltd bought 100,000 shares at 8.660CNY and the significance rating of the trade was 44/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

 PRESS RELEASE

DGAP-News: Bekanntmachung nach Art. 5 Abs. 4 b) und 5 der VO-EU Nr. 59...

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Schlagwort(e): Sonstiges Bekanntmachung nach Art. 5 Abs. 4 b) und 5 der VO-EU Nr. 596/2014 des EU Parlaments und des Rates vom 16.04.14 über Marktmissbrauch und gemäß Art. 6 Abs. 2 der DVO-EU 2016/1052 der Kommission vom 8.03.16 über die Durchführung von Stabilisierungsmaßnahmen 26.10.2018 / 17:26 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Korrektur der Bekanntmachung nach Artikel 5 Absatz 4 b) und Absatz 5 der Verordnung (EU) Nr. 596/2014 des Europäischen Parlaments und des Rates vom 16. April 2014 Ã...

 PRESS RELEASE

DGAP-News: Notification of Stabilisation Measures in accordance with A...

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Key word(s): Miscellaneous Notification of Stabilisation Measures in accordance with Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 on market abuse; Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052 on regulatory technical standards applicable to stabilisation measures 26.10.2018 / 17:26 The issuer is solely responsible for the content of this announcement. Correction of notification of Stabilisation Measures in accordance with Article 5 (4) (b) and (5) of Regulation (EU) No 596/2014 of the European Parliament and of the Council on ...

 PRESS RELEASE

DGAP-News: Joh. Berenberg, Gossler & Co. KG: Notification of Stabilisa...

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Key word(s): Miscellaneous/Miscellaneous Joh. Berenberg, Gossler & Co. KG: Notification of Stabilisation Measures in accordance with Article 5 (4) (b) and (5) of Reg. (EU) No 596/2014 on market abuse; Article 6 (2) of the Com. Delegated Reg. (EU) 2016/1052 on regulatory technical standards applicable to stabilisation measures 26.10.2018 / 15:59 The issuer is solely responsible for the content of this announcement. Notification of Stabilisation Measures in accordance with Article 5 (4) (b) and (5) of Regulation (EU) No 596/2014 of the European...

 PRESS RELEASE

DGAP-News: Joh. Berenberg, Gossler & Co. KG: Bekanntmachung nach Art. ...

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Schlagwort(e): Sonstiges/Sonstiges Joh. Berenberg, Gossler & Co. KG: Bekanntmachung nach Art. 5 Abs. 4 b) und 5 der VO-EU Nr. 596/2014 des EU Parlaments und des Rates vom 16.04.14 über Marktmissbrauch und gemäß Art. 6 Abs. 2 der DVO-EU 2016/1052 der Kommission vom 8.03.16 über die Durchführung von Stabilisierungsmaßnahmen 26.10.2018 / 15:59 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Bekanntmachung nach Artikel 5 Absatz 4 b) und Absatz 5 der Verordnung (EU) Nr. 596/2014 des Europäischen Parlaments und ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch